# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001641172-25-025379
Filing Date
2025-08-25
Accepted
2025-08-25 14:51:08
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | formdefa14a.htm | DEFA14A | 10149
2 | GRAPHIC | proxy_001.jpg | GRAPHIC | 286470
3 | GRAPHIC | proxy_002.jpg | GRAPHIC | 304533
| Complete submission text file | 0001641172-25-025379.txt |  | 825453

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 251250292
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)